Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Ribupatide

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

Fujian Shengdi Pharmaceutical Co · Phase 3 · Recruiting · Enrollment 140

NCT06974851

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Group 1: HRS9531n/rn/rn/rn/r
Group 2: HRS9531placebon/rn/rn/rn/r

Not shown

  • Group 1: HRS9531: endpoint not reported
  • Group 2: HRS9531placebo: endpoint not reported